The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?

Author:

Badagliacca Roberto,Papa Silvia,D'Alto MicheleORCID,Ghio Stefano,Agostoni Piergiuseppe,Ameri Pietro,Argiento Paola,Brunetti Natale Daniele,Casamassima Vito,Casu GavinoORCID,Cedrone Nadia,Confalonieri Marco,Corda Marco,Correale Michele,D'Agostino Carlo,De Michele LucreziaORCID,Famoso Giulia,Galgano Giuseppe,Greco Alessandra,Lombardi Carlo Mario,Manzi Giovanna,Madonna Rosalinda,Mercurio Valentina,Mulè Massimiliano,Paciocco Giuseppe,Romaniello Antonella,Romeo Emanuele,Scelsi Laura,Serra WalterORCID,Stolfo DavideORCID,Toma Matteo,Vatrano Marco,Vitulo Patrizio,Vizza Carmine DarioORCID

Abstract

ObjectiveThe coronavirus disease 2019 (COVID-19) outbreak has led to significant restrictions on routine medical care. We conducted a multicentre nationwide survey of patients with pulmonary arterial hypertension (PAH) to determine the consequences of governance measures on PAH management and risk of poor outcome in patients with COVID-19.Materials and methodsThe present study, which included 25 Italian centres, considered demographic data, the number of in-person visits, 6-min walk and echocardiographic test results, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide test results, World Health Organization functional class assessment, presence of elective and non-elective hospitalisation, need for treatment escalation/initiation, newly diagnosed PAH, incidence of COVID-19 and mortality rates. Data were collected, double-checked and tracked by institutional records between March 1 and May 1, 2020, to coincide with the first peak of COVID-19 and compared with the same time period in 2019.ResultsAmong 1922 PAH patients, the incidences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19 were 1.0% and 0.46%, respectively, with the latter comparable to that in the overall Italian population (0.34%) but associated with 100% mortality. Less systematic activities were converted into more effective remote interfacing between clinicians and PAH patients, resulting in lower rates of hospitalisation (1.2% versus 1.9%) and related death (0.3% versus 0.5%) compared with 2019 (p<0.001). A high level of attention is needed to avoid the potential risk of disease progression related to less aggressive escalation of treatment and the reduction in new PAH diagnoses compared with 2019.ConclusionA cohesive partnership between healthcare providers and regional public health officials is needed to prioritise PAH patients for remote monitoring by dedicated tools.

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference34 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Cardiac patient care during a pandemic: how to reorganise a heart failure unit at the time of COVID-19;Agostoni;Eur J Prev Cardiol,2020

3. The European Society for Cardiology . ESC Guidance for the Diagnosis and Management of CV Disease During the COVID-19 Pandemic. www.escardio.org/Education/COVID-19-and-Cardiology Date last updated: February 10, 2022. Date last accessed: March 17, 2022.

4. Triage considerations for patients referred for structural heart disease intervention during the coronavirus disease 2019 (COVID-19) pandemic: an ACC/SCAI consensus statement;Shah;J Am Coll Cardiol Intv,2020

5. Management of Acute Myocardial Infarction During the COVID-19 Pandemic

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3